Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 4/20 | 0.41 |
| ▸ | FNTB | P49356 | 4/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5555501 | 0.81 | GPBAR1 (0.45) | LRRK2TSHRFNTAFNTBPGGT1B | |
| SCHEMBL14379734 | 0.79 | ALDH1A1 (0.50) | LRRK2 | |
| SCHEMBL11744305 | 0.76 | S1PR2 (0.40) | LRRK2TSHR | |
| SCHEMBL1399326 | 0.73 | CYP1A2 (0.56) | TSHRLMNA | |
| SCHEMBL29514489 | 0.73 | CYP1A2 (0.56) | TSHRLMNA | |
| SCHEMBL1399302 | 0.72 | CNR2 (0.50) | LRRK2TSHR | |
| SCHEMBL1472952 | 0.72 | TSHR (0.67) | LRRK2TSHRARLMNA | |
| SCHEMBL3175405 | 0.71 | NPC1 (0.41) | TSHR | |
| SCHEMBL18406703 | 0.70 | FNTA (0.50) | LRRK2TSHRFNTAFNTBPGGT1B | |
| SCHEMBL7572084 | 0.69 | PLA2G7 (0.49) | LRRK2TSHRFNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014792-A1 | Process for preparation of pyridine derivatives | ROCHE PALO ALTO LLC | 2005-01-20 | — | — | US | claimed |
| EP-1656351-B1 | PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-7288658-B2 | Process for preparation of pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1656351-A1 | PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005014549-A1 | PROCESS FOR PREPARATION OF 4-ARYL-NICOTINAMIDE DERIVATIVES | F. HOFFMANN-LA-ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-20050014792-A1 | Process for preparation of pyridine derivatives | ROCHE PALO ALTO LLC | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014792-A1 | Process for preparation of pyridine derivatives | NOX3, KMO, PBK | LRRK2 4689/4885TSHR 2144/4885FNTA 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.